Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04547504
Title PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 %
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors University Hospital, Brest
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Pemetrexed Disodium

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries

Additional content available in CKB BOOST